Is Akebia Therapeutics, Inc. overvalued or undervalued?

As of 6 March 2017, Akebia Therapeutics, Inc. has moved from a valuation grade of "does not qualify" to "risky." The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of 42.42, an EV to EBITDA of 106.74, and a ROE of -184.16%. These figures indicate significant financial distress and lack of profitability.
In comparison to its peers, Akebia's P/E ratio is notably negative at -20.31, while Ocular Therapeutix, Inc. has a P/E of -6.73 and Vanda Pharmaceuticals, Inc. stands at -5.98. The high Price to Book Value and negative profitability ratios suggest that Akebia is not only overvalued but also carries substantial risk compared to its peers. Despite recent strong stock performance against the S&P 500, the underlying financial metrics indicate that the current valuation does not reflect the company's financial health.